Typhoid Conjugate Vaccine

In collaboration with PATH, EuBiologics targets to develop a typhoid conjugate vaccine (TCV) that can be co-administered with pediatric vaccines in both single- and multi-dose vials. The scope of work for this project includes Phase II and III clinical studies in African countries, and submission of WHO Pre-Qualification dossier. Development of TCVs can overcome the growing problem of antibiotic resistance in the treatment of typhoid; it also holds the promise of providing longer-lasting protection with fewer doses for children under two years of age. Although there are numerous TCV candidates currently in development, many are limited to single-dose vials and can be co-administered only with measles vaccine. EuTCV can be co-administered with both measles-rubella and yellow fever vaccines for incorporation into routine EPI programs.